Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

Peer Review reports

Original Submission
15 May 2017	Submitted	Original manuscript
31 Aug 2017	Author responded	Author comments - Carsten Ohlmann
Resubmission - Version 2
31 Aug 2017	Submitted	Manuscript version 2
13 Sep 2017	Author responded	Author comments - Carsten Ohlmann
Resubmission - Version 3
13 Sep 2017	Submitted	Manuscript version 3
Publishing
14 Sep 2017	Editorially accepted
4 Oct 2017	Article published	10.1186/s13063-017-2195-x

Back to article page